Vassilev LT - Search Results

1

In vivo activation of the p53 pathway by small-molecule antagonists of MDM2.

Vassilev LT, Vu BT, Graves B, Carvajal D, Podlaski F, Filipovic Z, Kong N, Kammlott U, Lukacs C, Klein C, Fotouhi N, Liu EA. Vassilev LT, et al. Science. 2004 Feb 6;303(5659):844-8. doi: 10.1126/science.1092472. Epub 2004 Jan 2. Science. 2004. PMID: 14704432

2

Targeting the p53-MDM2 interaction to treat cancer.

Klein C, Vassilev LT. Klein C, et al. Among authors: vassilev lt. Br J Cancer. 2004 Oct 18;91(8):1415-9. doi: 10.1038/sj.bjc.6602164. Br J Cancer. 2004. PMID: 15452548 Free PMC article. Review.

3

Small-molecule inhibitors of the p53-MDM2 interaction.

Vu BT, Vassilev L. Vu BT, et al. Curr Top Microbiol Immunol. 2011;348:151-72. doi: 10.1007/82_2010_110. Curr Top Microbiol Immunol. 2011. PMID: 21046355 Review.

4

Activation of p53 by MDM2 antagonists can protect proliferating cells from mitotic inhibitors.

Carvajal D, Tovar C, Yang H, Vu BT, Heimbrook DC, Vassilev LT. Carvajal D, et al. Among authors: vassilev lt. Cancer Res. 2005 Mar 1;65(5):1918-24. doi: 10.1158/0008-5472.CAN-04-3576. Cancer Res. 2005. PMID: 15753391

5

Development of E3-substrate (MDM2-p53)-binding inhibitors: structural aspects.

Fry DC, Graves B, Vassilev LT. Fry DC, et al. Among authors: vassilev lt. Methods Enzymol. 2005;399:622-33. doi: 10.1016/S0076-6879(05)99041-1. Methods Enzymol. 2005. PMID: 16338385

6

Small-molecule MDM2 antagonists reveal aberrant p53 signaling in cancer: implications for therapy.

Tovar C, Rosinski J, Filipovic Z, Higgins B, Kolinsky K, Hilton H, Zhao X, Vu BT, Qing W, Packman K, Myklebost O, Heimbrook DC, Vassilev LT. Tovar C, et al. Among authors: vassilev lt. Proc Natl Acad Sci U S A. 2006 Feb 7;103(6):1888-93. doi: 10.1073/pnas.0507493103. Epub 2006 Jan 27. Proc Natl Acad Sci U S A. 2006. PMID: 16443686 Free PMC article.

7

Activation of the p53 pathway by small-molecule-induced MDM2 and MDMX dimerization.

Graves B, Thompson T, Xia M, Janson C, Lukacs C, Deo D, Di Lello P, Fry D, Garvie C, Huang KS, Gao L, Tovar C, Lovey A, Wanner J, Vassilev LT. Graves B, et al. Among authors: vassilev lt. Proc Natl Acad Sci U S A. 2012 Jul 17;109(29):11788-93. doi: 10.1073/pnas.1203789109. Epub 2012 Jun 28. Proc Natl Acad Sci U S A. 2012. PMID: 22745160 Free PMC article.

8

MDM2 small-molecule antagonist RG7112 activates p53 signaling and regresses human tumors in preclinical cancer models.

Tovar C, Graves B, Packman K, Filipovic Z, Higgins B, Xia M, Tardell C, Garrido R, Lee E, Kolinsky K, To KH, Linn M, Podlaski F, Wovkulich P, Vu B, Vassilev LT. Tovar C, et al. Among authors: vassilev lt. Cancer Res. 2013 Apr 15;73(8):2587-97. doi: 10.1158/0008-5472.CAN-12-2807. Epub 2013 Feb 11. Cancer Res. 2013. PMID: 23400593

9

Discovery of RG7388, a potent and selective p53-MDM2 inhibitor in clinical development.

Ding Q, Zhang Z, Liu JJ, Jiang N, Zhang J, Ross TM, Chu XJ, Bartkovitz D, Podlaski F, Janson C, Tovar C, Filipovic ZM, Higgins B, Glenn K, Packman K, Vassilev LT, Graves B. Ding Q, et al. Among authors: vassilev lt. J Med Chem. 2013 Jul 25;56(14):5979-83. doi: 10.1021/jm400487c. Epub 2013 Jul 16. J Med Chem. 2013. PMID: 23808545

10

Phosphorylation of p53 on key serines is dispensable for transcriptional activation and apoptosis.

Thompson T, Tovar C, Yang H, Carvajal D, Vu BT, Xu Q, Wahl GM, Heimbrook DC, Vassilev LT. Thompson T, et al. Among authors: vassilev lt. J Biol Chem. 2004 Dec 17;279(51):53015-22. doi: 10.1074/jbc.M410233200. Epub 2004 Oct 6. J Biol Chem. 2004. PMID: 15471885 Free article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

90 results

Search Page